Fresenius Medical Care (NYSE:FMS) Upgraded by StockNews.com to Strong-Buy Rating

Fresenius Medical Care (NYSE:FMS) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday.

Several other equities analysts have also issued reports on FMS. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial boosted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Finally, Berenberg Bank initiated coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $24.30 on Wednesday. The stock has a market cap of $14.26 billion, a PE ratio of 20.08, a price-to-earnings-growth ratio of 0.82 and a beta of 0.93. The stock has a 50-day moving average of $23.33 and a 200-day moving average of $21.32. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care has a one year low of $17.93 and a one year high of $25.25.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The firm had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.36 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. During the same quarter in the previous year, the company earned $0.31 earnings per share. As a group, sell-side analysts expect that Fresenius Medical Care will post 1.53 earnings per share for the current year.

Institutional Investors Weigh In On Fresenius Medical Care

Large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Fresenius Medical Care in the 4th quarter worth $405,000. Assetmark Inc. lifted its holdings in shares of Fresenius Medical Care by 196.3% in the fourth quarter. Assetmark Inc. now owns 7,210 shares of the company’s stock valued at $163,000 after purchasing an additional 4,777 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Fresenius Medical Care by 40.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 31,074 shares of the company’s stock worth $704,000 after buying an additional 8,913 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock worth $102,000 after buying an additional 2,012 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.